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Abstract
The CRISPR‐Cas9 system has become increasingly popular for genome engineering
across all fields of biological research, including in the Gram‐positive model organism
Bacillus subtilis. A major drawback for the commercial use of Cas9 is the IP landscape
requiring a license for its use, as well as reach‐through royalties on the final product.
Recently an alternative CRISPR nuclease, free to use for industrial R&D, MAD7 was
released by Inscripta (CO). Here we report the first use of MAD7 for gene editing in
B. subtilis, in which editing rates of 93% and 100% were established. Additionally, we
engineer the first reported catalytically inactive MAD7 (dMAD7) variant (D877A,
E962A, and D1213A) and demonstrate its utility for CRISPR interference (CRISPRi)
at up to 71.3% reduction of expression at single and multiplexed target sites within
B. subtilis. We also confirm the CRISPR‐based editing mode of action in B. subtilis
providing evidence that the nuclease‐mediated DNA double‐strand break acts as a
counterselection mechanism after homologous recombination of the donor DNA.
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1 | INTRODUCTION
In recent years, precise genome editing with clustered regularly inter-
spaced short palindromic repeats (CRISPR)‐associated (Cas) systems have
become widely used in many fields of biology (Jinek et al., 2012), enabling
significant advances in genome editing tools for industrially relevant mi-
croorganisms, such as Bacillus subtilis (Altenbuchner, 2016; Burby &
Simmons, 2017; Price, Cruz, Baxter, Escalettes, & Rosser, 2019; West-
brook, Moo‐Young, & Chou, 2016b). Since the adaptation of the type II
CRISPR‐Cas9 system from Streptococcus pyogenes in 2012 for genomic
engineering, along with subsequent iterations—including but not limited
to CRISPR interference (CRISPRi) and CRISPR activation systems—it has
become the most broadly utilized CRISPR based system in prokaryotes
and eukaryotes (Altenbuchner, 2016; Burby & Simmons, 2017; Dicarlo
et al., 2013; Jakočiūnas, Jensen, & Keasling, 2015; Jakutyte‐Giraitiene &
Gasiunas, 2016; Jinek et al., 2012; Lu et al., 2019; Peng et al., 2017;
Peters et al., 2016; Price et al., 2019; Westbrook et al., 2016b; K. Zhang,
Duan, & Wu, 2016; Zhu et al., 2017). Cas9 induces a blunt DNA double‐
strand break (DSB) when in complex with either a two‐component
crRNA–tracrRNA or where these are combined into a single guide RNA
complex (Jinek et al., 2012). Previous literature describes that once the
DSB is introduced, it can be repaired by nonhomologous end‐joining
(NHEJ), or by homology directed repair (HDR) when a donor template
DNA (dDNA) is supplied (Adli, 2018; Altenbuchner, 2016; Burby &
Simmons, 2017; Jinek et al., 2012; Westbrook, Moo‐Young, &
Chou, 2016a). The inefficiency or total lack of an NHEJ system within
most bacteria limits the choice for repair of the cut to HDR in most of
these hosts (Shuman & Glickman, 2007).
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CRISPRi in bacteria functions through the targeting of a cataly-
tically inactive (D10A and H840A) Cas9 variant, dCas9 to the pro-
moter or within the 5′ region of a gene of interest. This sterically
hinders transcription by the RNA polymerase, thus lowering the
successful expression of the target gene (Qi et al., 2013). CRISPRi has
been exemplified within the Gram‐positive model organism Bacillus
subtilis (Westbrook et al., 2016b), perhaps most notably by Peters
et al. (2006) for the functional analysis of all essential genes.
An alternative CRISPR nuclease family, Cpf1 (also known as Cas12a),
has similarly been used for genome editing since the first report in 2015
(Zetsche et al., 2015). Cpf1 nucleases exhibit different characteristics to
Cas9 nucleases, such as a staggered DSB, a T‐rich PAM and the native
use of only 1 guide RNA molecule to form a complex with Cpf1 and
target the DNA. These characteristics enable Cpf1 nucleases to be used
in target organisms or regions within an organism's genome were a lower
GC content makes the use of Cas9 less feasible.
While the commercial application of Cas9 nucleases, and in-
creasingly also Cpf1 nucleases, have been widely pursued, a sig-
nificant drawback for the use of these nucleases is the requirement
of a research license and potentially subsequent royalty fees for the
commercial exploitation of any developed product.
Recently, Inscripta (CO) released the alternative CRISPR nucle-
ase MAD7 which is free for all commercial or academic research with
no reach‐through royalties or costs provided the final engineered
strain does not contain the MAD7 nuclease (Inscripta, 2019b). As
such, its use for commercial genome editing is of great interest. In-
scripta report that MAD7 was developed from Eubacterium rectale
and has proven its functionality in E. coli, S. cerevisiae and in the
human HEK293T cell line. Recently, MAD7 (also known as ErCas12a)
was shown to be compatible with genome editing in Zebrafish
(Wierson et al., 2019). MAD7 has 31% identity with Acidaminococcus
sp. BV3L6 Cpf1 (AsCpf1), to which it also shares a T‐rich PAM site
(5′‐YTTN‐3′), and a protospacer (the region of the gRNA which as-
sociates the nuclease to the DNA target) length of 21 nucleotides
(Inscripta, 2019a). A catalytically inactive variant of MAD7 has the
potential to be combined with inactive dCas9 and/or ddCpf1 based
tools to enable the construction of increasingly sophisticated syn-
thetic biology genetic circuits.
Several CRISPR genome modification systems have been re-
ported for use in the Gram‐positive model organism Bacillus subtilis
based around the efficient homologous recombination (HR) machin-
ery, all of which utilize the Cas9 nuclease (Altenbuchner, 2016; Burby
& Simmons, 2017; Price et al., 2019; Westbrook et al., 2016b;
K. Zhang et al., 2016), or recently also the partially inactivate nCas9
(D10A) (Liu et al., 2019). Here we demonstrate that CRISPR‐Cas9
genome editing in B. subtilis 168 is driven primarily by HR by curing B.
subtilis 168 tryptophan auxotrophy. Subsequently, we show editing
with MAD7 is also driven primarily by HR. We used the reporter
proteins, AmyE and GFPmut3, to analyze the editing efficiency of this
CRISPR‐MAD7 system and engineered MAD7 to generate the first
reported catalytically inactive, “dead,” MAD7 (dMAD7) for single
target and multiplexed transcriptional downregulation by dMAD7‐
mediated CRISPRi.
2 | MATERIALS AND METHODS
2.1 | Strains and media
The strains and plasmids used in this study are listed in Table S1.
All oligonucleotides used in this study are listed in Table S2.
Escherichia coli Top10 cells were used to construct recombinant
plasmids. Bacterial cells were cultured in Lysogeny broth (LB)
broth or LB agar (VWR) media at 37°C with agitation (250 rpm)
where appropriate. B. subtilis 168 tryptophan auxotrophy or pro-
totrophy were selected for by growth on M9 agar supplemented
with or without 20 µg/mL tryptophan (Harwood & Cutting, 1990).
When required, the following antibiotics were supplied to the
media: ampicillin (200 µg/mL), chloramphenicol (10 µg/mL), and
kanamycin (E. coli: 100 µg/mL; B. subtilis: 10 µg/mL).
2.2 | Plasmid and strain construction
Unless otherwise stated, plasmid construction was performed as
described in Sambrook and Russell (2001). DNA oligonucleotides
were purchased from Merck or Integrated DNA Technologies. The
reagents for polymerase chain reaction (PCR), restriction digest,
DNA phosphorylation, and ligation were purchased from New
England Biolabs (NEB). DNA purification was performed using the
Monarch® Nucleic Acid Purification Kits from NEB. DNA sequences
were confirmed by Source Bioscience.
2.2.1 | CRISPR plasmid construction
pBAC0155 was constructed using the inABLE plasmid assembly
method (Che, Knight, Canton, Kelly, & Shetty, 2015; Price et al., 2019).
Individual 5′ truncated parts were prepared by PCR followed by re-
striction digest at 5′ and 3′ regions with SapI. Where parts <120 base
pair (bp) were used, complementary oligonucleotides were phos-
phorylated and annealed leaving three nucleotides (nts) single strands
at both the 5′ and 3′ ends to remove the need for SapI digestion. The
parts were ligated to phosphorylated and annealed oligonucleotides at
each terminus, containing 3 nt and 16 nt single strands at the 5′ and
3′ ends, respectively. The part‐ oligonucleotides fusions were annealed
at the homologous 16 nt overhangs for 1 hr at 37°C, and used to
transform electrocompetent E. coli.
pBAC0155 consisted of four parts: 1. the E. coli/B. subtilis shuttle
vector backbone from pBAC0001; 2. the LacI repressor and isopropyl
β‐D‐1‐thiogalactopyranoside (IPTG) inducible Pgrac promoter from
pBAC0001, including a multiple cloning site; 3. the bidirectional strong
rrnB T1 and T2 terminators; 4. the MAD7 gRNA expression module
consisting of the Pveg promoter, the “MAD7 handle” section of the
gRNA and spacer DNA flanked by SapI sites for cloning of the pro-
tospacer DNA. Three 5′ truncated parts were prepared by PCR from
the indicated template and oligonucleotides: 1. pBAC0001 with
oMAP0010/0011; 2. pBAC0001 with oMAP0018/0019; 3. pING0001
2 | PRICE ET AL.
with oMAP0024/0025. The short part 4 was prepared as described
from oMAP0492/0493. Parts were ligated at 5′ and 3′ respectively
with annealed oligonucleotides: 1. oMAP0008/0009 and oMAP0014/
0015; 2. oMAP0016/0017 and oMAP0020/0021; 3. oMAP0022/0023
and oMAP0486/0487; 4. oMAP0488/0489 and oMAP0498/0499.
pBAC0158 was constructed by digesting pBAC0155 and pMK‐RQ‐
MAD7 (MAD7, codon‐optimized for B. subtilis and flanked by BamHI and
XbaI recognition sites, synthesized by Thermo Fisher Scientific) with
BamHI and XbaI restriction enzymes, and ligating the pBAC0155 back-
bone with the MAD7 gene using T4 DNA ligase.
pBAC0184, pBAC0194, and pBAC0195 were constructed by PCR
amplifying dCas9 from pdCas9‐bacteria with oligonucleotides
oMAP0073/0074, introducing a BsaI site and XbaI recognition sites at
the 5′ and 3′ end of the gene, respectively. The amplified dcas9 was
digested with BsaI and XbaI. pBAC0041, pBAC0035, and pBAC0165
were digested with BamHI and XbaI to remove the cas9 gene. The
dcas9 gene fragment was subsequently ligated with the pBAC0041/
0035/0165 backbones using T4 DNA ligase. pdCas9‐bacteria was a
gift from Stanley Qi (plasmid #44249; Addgene; Qi et al., 2013).
pBAC0187, pBAC0188, pBAC0189, and pBAC0190 were con-
structed by digesting pBAC0158, pBAC0162, pBAC0163, and
pBAC0166, respectively, as well as pMK‐RQ‐dMAD7 (dMAD7 [MAD7
gene with D877A [codon GCT to GAT], E962A [codon GCA to GAA],
D1213A [codon GCT to GAT] modifications] flanked by BamHI and XbaI
recognition sites, synthesised by Thermo Fisher Scientific), with BamHI
and XbaI. The dMAD7 gene fragment was subsequently ligated with the
pBAC0158/0162/0163/0166 backbones using T4 DNA ligase.
The protospacer insertion into pBAC0015, for the completion of
Cas9‐mediated genome editing plasmids, was carried out as pre-
viously described (Price et al., 2019). The construction of CRISPR
plasmids for MAD7 or dMAD7 was carried out in a similar fashion,
however SapI, instead of AarI, was used to cleave the pBAC0158 and
pBAC0187 backbones to yield 3 nt single‐stranded DNA overhangs
compatible with the gRNA protospacer constructed by annealing of
an oligonucleotide pair. All protospacer regions were identified using
the online tool, CHOPCHOP (Labun, Montague, Gagnon, Thyme, &
Valen, 2016; Montague, Cruz, Gagnon, Church, & Valen, 2014).
The following plasmids for Cas9‐mediated editing were pre-
pared with the pBAC0015 backbone using the indicated oligo-
nucleotide pairs: pBAC0129 (oMAP0386/0387); pBAC0165
(oMAP0573/0574); pBAC0185 (oMAP0694/0695). The following
plasmids for MAD7‐mediated editing were prepared from the
pBAC00158 backbone using the indicated oligonucleotide pairs:
pBAC0162 (oMAP0549/0550); pBAC0163 (oMAP0553/0554);
pBAC0166 (oMAP0571/0572); pBAC0218 (oMAP0799/0800).
The following plasmids where prepared from the pBAC0187
backbone using the indicated oligonucleotide pairs: pBAC0207
(oMAP0759/0760); pBAC0208 (oMAP0761/0762); pBAC0209
(oMAP0763/0764); pBAC0210 (oMAP0765/0766); pBAC0211
(oMAP0767/0768); pBAC0212 (oMAP0769/0770); pBAC0213
(oMAP0771/0772); pBAC0214 (oMAP0775/0776); pBAC0215
(oMAP0777/0778); pBAC0219 (oMAP0793/0794); pBAC0220
(oMAP0797/0798); and pBAC0222 (oMAP0795/0796).
Schematic representations of plasmids pBAC0015, pBAC0155,
pBAC0158, and pBAC0187 can be found in the supplementary
information.
2.2.2 | dDNA preparation
dDNA, encoding a programmed target site edit together with a sy-
nonymous PAM mutation to eliminate Cas9 or MAD7 cleavage at the
edited site after HR or HDR was constructed by overlap extension
PCR (OE‐PCR) as described previously (Bryksin & Matsumura, 2010;
Price et al., 2019).
2.2.3 | Strain construction
BAC0111 was constructed by transforming naturally competent B.
subtilis 168 with the integration plasmid pGFPbglS (Anagnostopoulos
& Spizizen, 1961; Bennallack, Burt, Heder, Robison, & Griffitts, 2014;
Bisicchia, Botella, & Devine, 2010). Transformants were selected on
LB agar plates supplemented with kanamycin (Figure S1).
A total of 1 µg of an OE‐PCR product generated using the oligonu-
cleotides set oMAP0388/0393/0394/0395 and the genomic DNA
(gDNA) of strain BAC0111 as template was co‐transformed alongside
200ng of the editing plasmid pBAC0129 for the modification of
BAC0111 to insert Pveg upstream of gfpmut3. The editing plasmid was
removed from the edited strain by overnight growth in LB supplemented
with 1mmol/L IPTG and subsequent confirmation by counter plating on
LB agar plates with and without chloramphenicol, yielding strain
BAC0288 (Figure S1; Price et al., 2019). The insertion of Pveg was verified
by sequencing and by fluorescence emission analysis using Safe Imager
2.0 Blue Light Transilluminator and Amber Filter System (excitation:
470 nm, emission: 530 nm; Thermo Fisher Scientific) to detect GFPmut3.
BAC0348‐0355 and BAC0360‐0368 were constructed by
transforming naturally competent cells of the relevant parental strain
with the appropriate plasmid (Table S1; Anagnostopoulos &
Spizizen, 1961; Bennallack et al., 2014). Transformants were selected
on LB agar plates supplemented with chloramphenicol.
2.3 | CRISPR‐Cas9/MAD7‐Mediated gene editing in
B. subtilis
A single OE‐PCR product was used to allow a direct comparison between
Cas9 and MAD7 editing efficiencies at the amyE locus. The OE‐PCR
product generated using the oligonucleotide set oMAP0121/0551/0552/
0122 was co‐transformed alongside the editing plasmids pBAC0041 and
pBAC0162.
dDNA for gfpmut3 editing was generated by PCR using oligos
oMAP0575/0578 and the synthesized plasmid pMK‐RQ‐gfpmut3‐
dDNA as a template.
Genome editing was carried out in triplicate by co‐transforming
naturally competent B. subtilis with 200ng editing plasmid DNA and 1µg
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dDNA (Anagnostopoulos & Spizizen, 1961; Bennallack et al., 2014; Price
et al., 2019). When targeting gfpmut3, transformants were spread on LB
agar plates supplemented with chloramphenicol and IPTG (1mmol/L).
Effective knock‐out of gfpmut3 by stop codon introduction was de-
termined by analysis of fluorescence emission using Safe Imager 2.0 Blue
Light Transilluminator and Amber Filter System (excitation: 470 nm,
emission: 530 nm; Thermo Fisher Scientific). Genotypes were confirmed
by colony PCR with oligonucleotides hybridizing to the chromosome
(oMAP0393/0814) outside of the dDNA homology arm region and se-
quenced with primer oMAP0815 to ensure accurate coverage of the
targeted region. When targeting amyE, transformants were spread on LB
agar plates supplemented with chloramphenicol, IPTG (1mmol/L) and 1%
soluble potato starch (VWR). Effective knock‐out of amyE by stop codon
introduction was determined by staining transformation plates with io-
dine (Price et al., 2019; Zhang, Yan, Cui, Hong, & Li, 2006). Genotypes
were confirmed by colony PCR with oligonucleotides hybridizing to the
chromosome (oMAP0811/0812) outside of the dDNA homology arm
region and sequenced with primer oMAP0813 to ensure accurate cov-
erage of the targeted region.
2.4 | Restoring B. subtilis tryptophan prototrophy
The CRISPR‐Cas9 genome editing mechanism in B. subtilis was in-
vestigated by restoring tryptophan prototrophy when transforming an
OE‐PCR product (oligonucleotides set oMAP0236/0696/0697/0239 and
gDNA of B. subtilis 168 as template) containing the mutation needed to
remove the trpC2 lesion, in the presence and absence of editing plasmid
pBAC0185, or Nontargeting plasmid pBAC0035 (Altenbuchner, 2016).
Transformations were carried out in triplicate in naturally competent B.
subtilis as previously described, and tryptophan prototroph cells were
selected in M9 minimal medium (Anagnostopoulos & Spizizen, 1961;
Bennallack et al., 2014; Price et al., 2019). Before spreading transfor-
mants on M9 agar plates, the cells were washed three times with
10mmol/L phosphate‐buffered saline to ensure there was no carryover
of tryptophan from the transformation process.
The CRISPR‐MAD7 genome editing mechanism in B. subtilis was
investigated in the same manner. OE‐PCR product (oligonucleotides
set oMAP0236/0801/0802/0239 and gDNA of B. subtilis 168 as
template) containing the mutation needed to remove the trpC2 lesion
was transformed in the presence and absence of editing plasmid
pBAC0218, or nontargeting plasmid pBAC0163. IPTG was included
in all transformation plates to limit the background of nonselected
colony forming units (CFUs).
Transformation results between different batches of competent
cells were normalized by the transformation efficiency obtained
when transforming only the nontargeting plasmid for the nuclease
being analyzed and selecting on LB agar supplemented with chlor-
amphenicol (Cas9), or LB agar supplemented with chloramphenicol
and IPTG (MAD7).
Unpaired t tests with Welch's correction were performed to de-
termine two‐tailed p values and identify statistically significant or non-
significant differences between the number of colonies obtained.
2.5 | Quantitative analysis of α‐amylase activity
Relative extracellular α‐amylase activity was quantified in the culture
supernatant of strains BAC0352‐0355 and BAC0360‐0363 using a
starch degradation assay. For each strain, an overnight culture was
used to inoculate a pre‐culture supplemented with chloramphenicol
and 1mmol/L IPTG. Once in exponential growth phase, the pre‐
culture was back diluted in triplicate into fresh and prewarmed
medium also supplemented with chloramphenicol and 1mmol/L IPTG
and grown for 24 hr. Supernatant samples were clarified by cen-
trifugation and 25 µL were mixed in triplicate with 100 µL assay so-
lution (50mmol/L Tris‐HCl, pH 6.8, 25mmol/L CaCl2, 0.05% [wt/vol]
soluble potato starch) and incubated for 30min at 37°C. 50 µL stop
solution (1mol/L HCl, 0.01% [wt/vol] I2, 0.1% [wt/vol] KI) was added
and absorbance at 620 nm measured. Unpaired t tests with Welch's
correction were performed to determine two‐tailed p values and
identify statistically significant or nonsignificant differences.
2.6 | Quantitative analysis of GFPmut3 expression
detection
Relative fluorescence was quantified in the cultures of strains
BAC0348‐0351 and BAC0364‐0368. For each strain, an overnight
culture was used to inoculate a pre‐culture supplemented with
chloramphenicol and 1mmol/L IPTG. Once in exponential growth
phase, the pre‐culture was back diluted into fresh and prewarmed
medium also supplemented with chloramphenicol and 1mmol/L IPTG
and grown for 24 hr. The culture fluorescence was measured in
samples of 100 µL using the FLUOstar Omega Microplate Reader
(BMG LABTECH) in 96‐well flat‐bottom plates (excitation: 485 nm;
emission: 520 nm; gain: 1,000; Greiner). Unpaired t tests with
Welch's correction were performed to determine two‐tailed p values
and identify statistically significant or nonsignificant differences.
3 | RESULTS
3.1 | Comparison of CRISPR‐Cas9 and
CRISPR‐MAD7 enabled genome editing efficiencies
To compare the gene‐editing efficiencies between Cas9 and MAD7 in
B. subtilis, chromosomally expressed amyE and gfpmut3 genes were
selected due to ease of analysis of successfully edited colonies by
starch degradation or fluorescence respectively. For both nucleases,
a single dDNA with 1 kbp homology arms, either side of the site
targeted for modification, was designed to introduce a stop codon at
the 5′ of the gene and remove the PAM sites selected based on their
proximity (Figure 1a,b).
Cas9 and MAD7 yielded amyE knock‐out efficiencies of 98% and
93% respectively when the editing plasmids were co‐transformed
with dDNA to B. subtilis 168 (Figure 1c). When knocking out gfpmut3,
editing efficiencies of 75% and 100% were observed for Cas9 and
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MAD7 respectively despite the lower transformation efficiency of
BAC0288 (Figure 1c). In the absence of dDNA, the DSB catalyzed by
either nuclease drastically reduces cell viability and no successfully
edited colonies were identified. Following phenotypic analysis, the
genotypes of a selected population of the transformants were con-
firmed by colony PCR and sequencing for both amyE and gfpmut3
(Table S3).
Nontargeting plasmids, containing a gRNA with a random DNA
sequence which does not target anywhere in the genome of B. subtilis
168 were transformed with and without dDNA for both amyE and
gfpmut3 to determine the basal level of editing in the absence of the
DSB induced by a CRISPR nuclease (Figure 1c). A basal level of editing
of 2 in 1,117 CFUs and 1 in 534 CFUs was phenotypically detected
when the dDNA for gfpmut3 editing was co‐transformed with the Cas9
or MAD7 nontargeting plasmids, respectively. In the case of amyE, no
edited colonies were detected with the same strategy. This highlights
the importance of having both the nuclease and targeting gRNA pre-
sent to ensure high editing efficiency is obtained due to the counter-
selection of unedited colonies. The higher number of colonies analyzed
following transformation of the nontargeting plasmids was due to the
absence of the selective pressure, against colony formation, in non‐
edited cells when a targeting gRNA is present.
F IGURE 1 CRISPR‐Cas9 or CRISPR‐MAD7‐mediated editing of amyE and gfpmut3. (a) Non‐edited (WT) and edited sequences with their
corresponding amino acid sequences (*=stop codon). The targeted PAM sites are indicated for both Cas9 and MAD7. The modified base pairs are
highlighted in bold and the introduced stop codons are marked with red boxes. (b) Co‐transformational editing approach were the CRISPR plasmid
expressing the gRNA and nuclease is transformed alongside a linear editing template (dDNA) containing the editing region. (c) Editing efficiency
following co‐transformation of B. subtilis 168 (amyE) or BAC0288 (gfpmut3). Bars represent the average editing efficiency obtained following
transformation of the targeting or nontargeting (NT) gRNA expression plasmids for each nuclease with or without dDNA (amyE targeting: Cas9:
pBAC0041; MAD7: pBAC0162. gfpmut3: Cas9: pBAC0165; MAD7: pBAC0166. NT: Cas9: pBAC0035; MAD7: pBAC0163). Editing efficiency (%)
was determined by observing either starch degradation or fluorescence in the transformation plates. The circled number above each bar indicates
the total number of colonies phenotypically screened. Error bars indicate the standard deviation between three independent transformation
events. dRNA, donor template DNA; gRNA, guide RNA; WT, wild‐type [Color figure can be viewed at wileyonlinelibrary.com]
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3.2 | Homologous recombination versus DNA
double‐strand break repair as the driving mechanism
for CRISPR genome editing in B. subtilis 168
To elucidate the mechanism with which CRISPR‐mediated editing takes
place in B. subtilis 168, we made use of this strain's tryptophan auxo-
trophy to compare the efficiency in restoring prototrophy when a linear
dDNA is transformed on its own, or in the presence of either a Cas9 or
MAD7 nontargeting or trpC2‐targeting plasmid. The linear dDNA, har-
boring 1 kbp homology regions either side of the site targeted for
modification, was designed to simultaneously introduce an additional
isoleucine residue adjacent to I110 residue of TrpC2, returning the
strain to a prototrophic state, and a synonymous mutation to eliminate
the PAM recognition site and prevent continuous cutting by the trpC2‐
targeting plasmid (Figure 2a,b; Altenbuchner, 2016). By selecting
transformants in M9 minimal medium supplemented with or without
either chloramphenicol (plasmid selection) or tryptophan, we could
clarify whether HR drives genome editing, preventing a DSB, or if the
DSB induces DNA repair by HR. As the procedure to induce natural
competence utilizes tryptophan within the growth medium throughout,
there is no selection for prototrophic cells before the spreading of the
transformants on the agar plates.
In the absence of tryptophan, there is not a significant difference in
CFU obtained when transforming the linear dDNA to restore tryptophan
prototrophy on its own or in the presence of either the trpC2 targeting or
nontargeting plasmids (Figure 2). Furthermore, when cells with restored
F IGURE 2 Restoration of B. subtilis prototrophy using CRISPR‐Cas9 and CRISPR‐MAD7 for genome editing. (a and b) show the non‐edited (WT) and
edited sequences for Cas9 and MAD7 editing respectively as well as their corresponding amino acid sequences. The modified base pairs are highlighted
in bold and the inserted isoleucine (Ile) codon, adjacent to I110, is marked with red boxes. (c) Co‐transformational editing approach were the CRISPR
plasmid expressing the gRNA and nuclease is transformed alongside a linear editing template (dDNA) containing the editing region. (d and e) Graphs
show the number of transformants following transformations with the indicated combinations of dDNA and targeting (pBAC0185 for Cas9 and
pBAC0218 for MAD7) or nontargeting plasmid (pBAC0035 for Cas9 and pBAC0163 for MAD7) to restore B. subtilis 168 prototrophy, with Cas9 and
MAD7, respectively. Bars represent the average number of colony‐forming unit (CFU) normalized by the transformation efficiency of pBAC0035 (Cas9)
selected on LB agar supplemented with chloramphenicol or pBAC0163 (MAD7) selected on LB agar supplemented with chloramphenicol and IPTG.
Error bars indicate the standard deviation between three independent transformation events. Cm, chloramphenicol; dRNA, donor template DNA; IPTG,
isopropyl β‐D‐1‐thiogalactopyranoside; LB, Lysogeny broth; Trp, tryptophan; WT, wild‐type [Color figure can be viewed at wileyonlinelibrary.com]
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prototrophy were also selected in the presence of chloramphenicol, there
was no significant difference between the co‐transformation of dDNA
with either the trpC2‐targeting or nontargeting CRISPR‐Cas9 plasmids
(Figure 2). Both these results indicate that HR is the main driving force
for CRISPR‐Cas9 editing in the presence of dDNA. When M9 was sup-
plemented with tryptophan, the absence of selective pressure for re-
stored prototrophy results in a significantly lower number of CFU when
co‐transforming the dDNA and the trpC2‐targeting plasmid compared
with the co‐transformation of dDNA with the nontargeting plasmid
(Figure 2). In this case, the lethal cut induced by the nuclease counter-
selects the transformants in which HR of dDNA has not occurred. As
such, while the high efficiency of HR is the main driving force for genome
editing, the nuclease induced DSB is essential to obtain high editing ef-
ficiency in B. subtilis 168.
3.3 | Engineering of MAD7 to construct and
characterize the catalytically inactive dMAD7
3.3.1 | Identification of MAD7 catalytic residues
A pairwise alignment of the amino acid sequences of MAD7 and
AsCpf1, confirmed the 31% identity (Figure S2). Previously, it was
reported that the catalytic residues of AsCpf1 are Asp908, Glu993,
and Asp1263 (Yamano et al., 2016; Zetsche et al., 2015). Asp908 lies
in a region of high similarity with MAD7, with residues 905‐916
corresponding to MAD7 residues 874‐885. AsCpf1 Glu993 does not
lie in a region of high homology, however, the alignment revealed
that this residue was conserved in MAD7. Finally, the residue cor-
responding to Asp1263 in AsCpf1 was found in a region on high
homology with AsCpf1, with residues 1261–1268 corresponding to
MAD7 residues 1211–1218. The corresponding catalytic residues in
MAD7 (Asp877, Glu962, and Asp1213) identified by sequence
homology (Figure S2) were simultaneously modified to alanine in
silico and the corresponding gene dMAD7 was synthesized.
3.3.2 | dMAD7 lacks the ability to induce a lethal
DNA double‐strand break
To verify whether the DNA cleavage capacity of MAD7 was removed in
the putative dMAD7, the synthesized dMAD7 gene was used to replace
MAD7 within the amyE and gfpmut3 targeting plasmids pBAC0162 and
pBAC0166, respectively. As a control, the well‐characterized dcas9 was
used to replace cas9 in plasmids pBAC0041 and pBAC0165 (Peters
et al., 2016; Qi et al., 2013; Westbrook et al., 2016b). Naturally compe-
tent B. subtilis 168 and BAC0288 were respectively transformed with the
amyE and gfpmut3 targeting plasmids with both active and inactive
nuclease variants. Triplicate transformations were spread on plates sup-
plemented with chloramphenicol and IPTG to ensure nuclease expres-
sion. The average number of CFUs obtained for each set of
transformations (Table 1) indicates that the engineered dMAD7 does
not catalyze DSB of DNA since it does not cause the reduced viability
observed for the catalytically active nuclease.
3.3.3 | dMAD7 retains DNA binding capacity to
enable CRISPRi
Extracellular α‐amylase activity was quantified in strains ex-
pressing dMAD7 targeting five PAM sites (5′‐TTTN‐3′) at the 5′
end of amyE, two on the template strand and three on the non‐
template strand. The results were directly compared with strains
expressing dCas9 targeting amyE +25 bases downstream of the
start codon. Strains expressing nontargeting dMAD7 and dCas9
plasmids were used as the negative controls for downregulation
(Figure 3a,b).
The results confirm that dCas9‐mediated CRISPRi is highly effi-
cient with a 99.4% reduction in α‐amylase activity, while dMAD7‐
mediated CRISPRi appears less efficient, ranging from 59.3% to
51.5% activity reduction depending on the gRNA and PAM site
sequence. The gRNA targeting the PAM site TTTG +21 bases from
the start codon did not exhibit significantly reduced levels of activity.
As this PAM sequence was the same as others where CRISPRi was
successful, and the GC % of the protospacer (28.6%) is similar to the
one targeting the PAM site +4 (33.3%), we hypothesize the cause of
this lowered efficiency is due to secondary structure within the
gRNA, as has previously been reported for Cas9 (Thyme, Akhmetova,
Montague, Valen, & Schier, 2016; Xu, Lian, Jia, Li, & Huang, 2017).
To further investigate the capacity of dMAD7 for CRISPRi, the
gfpmut3 gene in strain BAC0288 was targeted. Here, six PAM sites
(three on each strand) where targeted with the 5′‐YTTN‐3′ PAM
sequence recommended by Inscripta (Figure 3c). dMAD7 was
targeted to the 5′ end of gfpmut3 and fluorescence was compared
with strains expressing dCas9 targeting gfpmut3 +27 bases down-
stream of the start codon. Strains expressing nontargeting dMAD7
and dCas9 plasmids were used as negative controls for
TABLE 1 Average number of transformants (CFU) obtained
following triplicate transformation reactions of naturally competent
B. subtilis 168 and BAC0288 with 200 ng of Cas9, dCas9, MAD7, and
dMAD7 plasmids
Parental
strain Target Plasmid Nuclease
Average CFU
obtained








Abbreviation: CFU, colony‐forming unit.
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downregulation (Figure 3d). Here, a broader effect on expression was
observed for dMAD7 with statistically significant CRISPRi effi-
ciencies ranging from 71.3% to 26.8%. Once again, the gfpmut3 tar-
geting dCas9 control exhibited highly efficient CRISPRi with a 95.1%
reduction in expression. This difference in efficiency may indicate
that further modifications to dMAD7 could be made to increase its
ability to bind DNA efficiently.
3.3.4 | Multiplexed CRISPRi of amyE and gfpmut3
with dMAD7
To increase the efficiency of dMAD7 transcriptional downregulation,
multiplexed targeting, where more than one gRNA is utilized at a
time, was tested. gRNA arrays were inserted in the same manner as
single gRNAs, with the final array designed with the dMAD7 handle
direct repeat at both the 3′ and 5′ ends, as well as between the
inserted protospacers.
Additive downregulation of amyE was tested by targeting PAM sites
at +4 TTTG and +51 TTTA in strain BAC0377 (Figure 4b). Similarly,
gfpmut3 was analyzed by targeting PAM sites at +80 TTTC and +21
TTTG in strain BAC0380 (Figure 4b). These were compared with the
nontargeting dMAD7 control strain BAC0350, as well as the single gRNA,
amyE or gfpmut3 targeting dMAD7 strains BAC0381, BAC0382,
BAC0351, and BAC0368. To ensure the gRNA array was matured from a
single transcript into single gRNA units, strain BAC0378, carrying a gRNA
array to target amyE +4 TTTG and gfpmut3 +80 TTTC was analyzed for
transcriptional interference of both targets (Figure 4c).
The results show when amyE and gfpmut3 were simultaneously
targeted the downregulation of both genes was found to be similar to
when only one was targeted for CRISPRi (Figure 4c). As such, the
gRNA array was correctly matured to single gRNAs and there is no
significant competition between the two gRNAs for dMAD7‐
mediated CRISPRi.
When two gRNAs are combined to target either gfpmut3 or
amyE, the measured downregulation is not cumulative. As the
BAC0378 multiplexing results indicate no significant competition
between the gRNAs for dMAD7, it is thought that there is a potential
steric hindrance between the protospacer‐dMAD7 complexes used
to simultaneously target each reporter.
F IGURE 3 Relative α‐amylase activity and GFPmut3 fluorescence following dCas9 and dMAD7‐mediated CRISPRi. (a and c) Schematic
diagrams of gRNA binding sites for dMAD7 within amyE and gfpmut3 respectively. Values represent the distance of each targeted PAM site
from the start codon on either the template (blue) or non‐template (red) DNA strand. (b) Bar graph represents the extracellular α‐amylase
activity normalized by OD600 nm relative to the nontargeting gRNA control for either dMAD7 or dCas9, after 24 hr of growth. The horizontal
axis indicates the PAM site targeted by each gRNA for both dMAD7 and dCas9 and its distance to the amyE start codon (+4: BAC0360; +51:
BAC0363; +27: BAC0362; +11: BAC0361; +21: BAC0355; +25: BAC0353). Red and blue bars correspond to PAM sites on the non‐template
and template strands, respectively. Gray bars represent nontargeting controls (dMAD7: BAC0354; dCas9: BAC0352). (d) Bar graph represents
the fluorescence intensity normalized by OD600 nm relative to the nontargeting gRNA control for either dMAD7 or dCas9, after 24 hr of growth.
The horizontal axis indicates the PAM site targeted by each gRNA for both dMAD7 and dCas9 and its distance to the gfpmut3 start codon (+80:
BAC0368; +78: BAC0367; +21: BAC0351; +9: BAC0364; +16: BAC0365; +43: BAC0366; +27: BAC0349). Red and blue bars correspond to
PAM sites on the non‐template and template strands, respectively. Gray bars represent the nontargeting controls (dMAD7: BAC0350; dCas9:
BAC0348). Error bars indicate the standard deviation between three biological replicates. Two‐tailed p values following unpaired t test with
Welch's correction. gRNA, guide RNA; NS, not significant [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 4 Relative α‐amylase activity and GFPmut3 fluorescence following dMAD7‐mediated multiplexing CRISPRi in BAC0288.
(a) Schematic diagrams of gRNA binding sites for dMAD7 within amyE and gfpmut3. Values represent the distance of each targeted PAM site
from the start codon on the non‐template DNA strand. (b) Investigation for an additive multiplexed CRISPRi effect when two gRNAs target a
single gene. (c) Investigation for a multiplexed CRISPRi effect when two gRNAs target different genes within the same strain. Bars represent
extracellular α‐amylase activity, or GFPmut3 fluorescence intensity, normalized by OD600 nm, relative to the nontargeting gRNA control strain,
after 24 hr of growth. The horizontal axis indicates the targeted PAM site(s) distance to the amyE or gfpmut3 start codon (Strains used: +4:
BAC0381; +51: BAC0382;+4 and +51: BAC0377; +4 and +80: BAC0378; +80: BAC0368; +21: BAC0351; +80 and +21: BAC0380). White bars
indicate strains in which a single gRNA is utilized to target a single gene. Gray bars indicate strains in which the effect of two gRNAs on a single
gene is investigated. Blue bars indicate BAC0378 in which the effect of single gRNAs on two different genes is investigated. Red bars indicate
the negative control strain, BAC0350, in which a nontargeting gRNA is expressed alongside dMAD7. Error bars indicate the standard deviation
between three biological replicates. *p < .05; **p < .01. Two‐tailed p values were derived following unpaired t test with Welch's correction. gRNA,
guide RNA; NS, not significant [Color figure can be viewed at wileyonlinelibrary.com]
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4 | DISCUSSION
We have exemplified the first reported use of the CRISPR‐associated
nuclease MAD7 free for all commercial or academic research in the
Gram‐positive model organism, B. subtilis. The MAD7‐mediated gen-
ome editing efficiency determined by targeting amyE (93%) and
gfpmut3 (100%) was comparable to the commonly used Cas9 nuclease.
This indicates that MAD7 is a viable alternative to Cas9 for strain
development of the industrial workhorse B. subtilis. These results also
indicate that the killing efficiency of MAD7 (amyE: 99.84%; trpC2:
99.62%) in B. subtilis, determined by the total number of CFUs fol-
lowing transformation with targeting versus nontargeting plasmids
only, was similar to that of Cas9 (amyE: 99.98%; trpC2: 99.89%). It is
hypothesized that, due to the strong selection for survival, these “es-
caper” colonies may harbor mutations deactivating the killing capacity
of the CRISPR systems. Such mutations may occur within the editing
plasmid, or on the chromosome at the PAM site or the first 10–12 nt
of the gRNA protospacer (known as the seed region) within which any
mutations cause a severely deleterious effect on cleavage efficiency
(Jiang, Bikard, Cox, Zhang, & Marraffini, 2013; Jinek et al., 2012).
We have provided evidence that, in B. subtilis 168, CRISPR‐
Cas9 and CRISPR‐MAD7 genome editing efficiency is driven
primarily by HR of dDNA preventing the lethal Cas9 or MAD7‐
induced DNA DSB, rather than HDR following the DSB.
Mougiakos et al. reported the endogenous HR machinery within
Bacillus smithii incorporating plasmid‐borne dDNA while Cas9
was inactive at ≥42°C. Counterselection of the cells which had
not undergone HR was then performed at 37°C where the Cas9
was once again functional. Here we have shown HR as the driving
mechanism under temperatures where the nuclease is active and
growth is optimal (Mougiakos et al., 2017). The presence of the
CRISPR‐Cas9 or CRISPR‐MAD7 system was not required to de-
tect successful HR due to prototrophic selection on M9 minimal
medium. However, where such a selection is not possible, the
CRISPR‐Cas9 or CRISPR‐MAD7 systems act as a powerful
counterselection for unedited cells. Additionally, the editing
efficiency reported here with pBAC0041 and dDNA (Figure 1) in
the presence of IPTG for Cas9 expression induction (91%) is si-
milar to that previously reported in the absence of IPTG (89.2%;
Price et al., 2019). Thus, editing rates are decoupled from Cas9
expression levels with leaky Pgrac promoter activity being suffi-
cient to induce the lethal DSB. Moreover, as the natural compe-
tency master regulator ComK activates transcription of the
primary component of HR, recA, and DNA uptake is single‐
stranded, yielding a substrate with which RecA can bind, HR can
readily proceed at the target site before the DSB taking place
(Cheo, Bayles, & Yasbin, 1993; Dubnau, 1999).
Furthermore, a catalytically inactive variant of MAD7 was en-
gineered retaining its ability to bind DNA in the presence of a DNA‐
targeting gRNA. Our data highlights the importance of testing multiple
gRNA sequences when optimizing the MAD7‐mediated downregulation
of a target gene. The level of downregulation is likely influenced by a
combination of factors, such as PAM site sequence, gRNA binding
efficiency, GC % of the protospacer, and gRNA secondary structure
(Labun et al., 2016; Thyme et al., 2016; Wilson, O'Brien, & Bauer, 2018;
Zetsche et al., 2015). Interestingly, the significance of gRNA selection
does not seem to be as great when preforming MAD7‐mediated editing
compared to CRISPRi. The amyE +21 targeting PAM site resulted in 98%
editing efficiency while only showing a 7.9% decrease of α‐amylase ac-
tivity when preforming CRISPRi with dMAD7. This is likely because the
nuclease DSB is a single event whereas CRISPRi requires a stable and
continuous interaction between the nuclease and targeted coding se-
quence for efficient transcriptional downregulation. Multiplexed targeting
of dMAD7 to an endogenous and heterologous gene target was ex-
emplified, with no detectable competition between gRNAs on the pool of
expressed dMAD7 when compared to strains with only a single gRNA. It
is feasible that technologies developed were effector proteins are fused
to dCas9 for pathway optimization or in vivo mutagenesis could be
adapted for use with dMAD7 further expanding its potential (Bikard
et al., 2013; Wang et al., 2018; Yang et al., 2018).
An attractive feature of MAD7 is its freedom to use for industrial
R&D and commercial strain construction (provided the final strain
does not retain the MAD7 nuclease (Inscripta, 2019b)). This has the
capacity to disrupt the slow commercial uptake of genome editing
technologies allowing the use of MAD7 in sectors that were put off by
licensing and royalty fees associated with for instance Cas9 and Cpf1
CRISPR nucleases, such as large‐scale fermentation biotechnology.
ACKNOWLEDGMENTS
The authors also thank Inscripta Inc. for supplying the sequence of MAD7
as an open‐source nuclease for the gene‐editing community. The authors
declare R. C., and F. E.'s affiliation to Ingenza Ltd. The authors also declare
that no conflict of interests exists, there are no patents pending for this
research, and no products in the development of marketing.
ORCID
Marcus A. Price http://orcid.org/0000-0002-7435-873X
Susan J. Rosser http://orcid.org/0000-0002-2560-6485
REFERENCES
Adli, M. (2018). The CRISPR tool kit for genome editing and beyond. Nature
Communications, 9, 1911. https://doi.org/10.1038/s41467‐018‐04252‐2
Altenbuchner, J. (2016). Editing of the Bacillus subtilis genome by the
CRISPR‐Cas9 system. Applied and Environmental Microbiology, 82(17),
5421–5427. https://doi.org/10.1128/AEM.01453‐16
Anagnostopoulos, C., & Spizizen, J. (1961). Requirements for transformation in
Bacillus subtilis. Journal of Bacteriology, 81(5), 741–746.
Bennallack, P. R., Burt, S. R., Heder, M. J., Robison, R. A., & Griffitts, J. S.
(2014). Characterization of a novel plasmid‐borne thiopeptide gene
cluster in Staphylococcus epidermidis strain 115. Journal of Bacteriology,
196(24), 4344–4350. https://doi.org/10.1128/JB.02243‐14
Bikard, D., Jiang, W., Samai, P., Hochschild, A., Zhang, F., & Marraffini, L. A.
(2013). Programmable repression and activation of bacterial gene
expression using an engineered CRISPR‐Cas system. Nucleic Acids
Research, 41(15), 7429–7437. https://doi.org/10.1093/nar/gkt520
Bisicchia, P., Botella, E., & Devine, K. M. (2010). Suite of novel vectors for
ectopic insertion of GFP, CFP and IYFP transcriptional fusions in
single copy at the amyE and bglS loci in Bacillus subtilis. Plasmid, 64(3),
143–149. https://doi.org/10.1016/j.plasmid.2010.06.002
10 | PRICE ET AL.
Bryksin, A. V., & Matsumura, I. (2010). Overlap extension PCR cloning: A
simple and reliable way to create recombinant plasmids. Biotechniques,
48(6), 463–465. https://doi.org/10.2144/000113418
Burby, P. E., & Simmons, L. A. (2017). MutS2 promotes homologous
recombination in Bacillus subtilis. Journal of Bacteriology, 199(2),
https://doi.org/10.1128/JB.00682‐16
Che, A., Knight, T., Canton, B., Kelly, J., & Shetty, R. (2015). Iti Scotland
Limited. United States Patent No. US 8,999,679 B2. United States of
America.
Cheo, D. L., Bayles, K. W., & Yasbin, R. E. (1993). Elucidation of regulatory
elements that control damage induction and competence induction of
the Bacillus subtilis SOS system. Journal of Bacteriology, 175(18),
5907–5915. https://doi.org/10.1128/jb.175.18.5907‐5915.1993
Dicarlo, J. E., Norville, J. E., Mali, P., Rios, X., Aach, J., & Church, G. M.
(2013). Genome engineering in Saccharomyces cerevisiae using CRISPR‐
Cas systems. Nucleic Acids Research, 41(7), 4336–4343. https://doi.org/
10.1093/nar/gkt135
Dubnau, D. (1999). DNA uptake in bacteria. Annual Review of Microbiology,
53(1), 217–244. https://doi.org/10.1146/annurev.micro.53.1.217
Harwood, C. R., & Cutting, S. M. (1990). Molecular Biological Methods for
Bacillus. John Wiley & Sons.
Inscripta, I. (2019a). Introducing MAD7 | Inscripta. Retrieved from https://
www.inscripta.com/madzymes/
Inscripta, I. (2019b). MADzyme FAQs | Inscripta. Retrieved from https://
www.inscripta.com/madzymes/faq/
Jakočiūnas, T., Jensen, M. K., & Keasling, J. D. (2015). CRISPR/Cas9
advances engineering of microbial cell factories. Metabolic Engineering,
34, 44–59. https://doi.org/10.1016/j.ymben.2015.12.003
Jakutyte‐Giraitiene, L., & Gasiunas, G. (2016). Design of a CRISPR‐Cas
system to increase resistance of Bacillus subtilis to bacteriophage
SPP1. Journal of Industrial Microbiology & Biotechnology, 43(8),
1183–1188.
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. a (2013). RNA‐guided
editing of bacterial genomes using CRISPR‐Cas systems. Nature
Biotechnology, 31(3), 233–239. https://doi.org/10.1038/nbt.2508
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., &
Charpentier, E. (2012). A programmable dual‐RNA—Guided DNA
endonuclease in adaptive bacterial immunity. Science, 337, 816–822.
https://doi.org/10.1126/science.1225829
Labun, K., Montague, T. G., Gagnon, J. A., Thyme, S. B., & Valen, E. (2016).
CHOPCHOP v2: A web tool for the next generation of CRISPR
genome engineering. Nucleic Acids Research, 44(W1), W272–W276.
https://doi.org/10.1093/nar/gkw398
Liu, D., Huang, C., Guo, J., Zhang, P., Chen, T., Wang, Z., & Zhao, X.
(2019). Development and characterization of a CRISPR/Cas9n‐
based multiplex genome editing system for Bacillus subtilis.
Biotechnology for Biofuels, 12(1), 197. https://doi.org/10.1186/
s13068‐019‐1537‐1
Lu, Z., Yang, S., Yuan, X., Shi, Y., Ouyang, L., Jiang, S., & Zhang, G. (2019).
CRISPR‐assisted multi‐dimensional regulation for fine‐tuning gene
expression in Bacillus subtilis. Nucleic Acids Research, 13. https://doi.
org/10.1093/nar/gkz072
Montague, T. G., Cruz, J. M., Gagnon, J. A., Church, G. M., & Valen, E.
(2014). CHOPCHOP: A CRISPR/Cas9 and TALEN web tool for
genome editing. Nucleic Acids Research, 42(W1), W401–W407.
https://doi.org/10.1093/nar/gku410
Mougiakos, I., Bosma, E. F., Weenink, K., Vossen, E., Goijvaerts, K., Van
Der Oost, J., & Van Kranenburg, R. (2017). Efficient genome
editing of a facultative thermophile using mesophilic spCas9.
ACS Synthetic Biology, 6(5), 849–861. https://doi.org/10.1021/
acssynbio.6b00339
Peng, F., Wang, X., Sun, Y., Dong, G., Yang, Y., Liu, X., & Bai, Z. (2017).
Efficient gene editing in Corynebacterium glutamicum using the
CRISPR/Cas9 system. Microbial Cell Factories, 16(1), 201. https://doi.
org/10.1186/s12934‐017‐0814‐6
Peters, J. M., Colavin, A., Shi, H., Czarny, T. L., Larson, M. H., Wong, S., &
Gross, C. A. (2016). A comprehensive, CRISPR‐based functional
analysis of essential genes in bacteria. Cell, 165(6), 1493–1506.
https://doi.org/10.1016/j.cell.2016.05.003
Price, M. A., Cruz, R., Baxter, S., Escalettes, F., & Rosser, S. J. (2019).
CRISPR‐Cas9 In Situ engineering of subtilisin E in Bacillus subtilis.
PLoS One, 14(1), https://doi.org/10.1371/journal.pone.0210121
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S.,
Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an
RNA‐guided platform for sequence‐specific control of gene
expression. Cell, 152(5), 1173–1183. https://doi.org/10.1016/j.
cell.2013.02.022
Sambrook, J., & Russell, R. W. (2001). Molecular cloning: A laboratory
manual. 4th Ed.
Shuman, S., & Glickman, M. S. (2007). Bacterial DNA repair by non‐
homologous end joining. Nature Reviews Microbiology, 5(11), 852–861.
https://doi.org/10.1038/nrmicro1768
Thyme, S. B., Akhmetova, L., Montague, T. G., Valen, E., & Schier, A. F.
(2016). Internal guide RNA interactions interfere with Cas9‐mediated
cleavage. Nature Communications, 7(1), https://doi.org/10.1038/
ncomms11750
Wang, Y., Liu, Y., Liu, J., Guo, Y., Fan, L., Ni, X., & Ma, Y. (2018). MACBETH:
Multiplex automated Corynebacterium glutamicum base editing
method. Metabolic Engineering, 47, 200–210. https://doi.org/10.
1016/j.ymben.2018.02.016
Westbrook, A. W., Moo‐Young, M., & Chou, C. P. (2016a). Development of
a CRISPR‐Cas9 tool kit for comprehensive engineering of Bacillus
subtilis. Applied and Environmental Microbiology, 82(16), 4876–4895.
https://doi.org/10.1128/AEM.01159‐16
Westbrook, A. W., Moo‐Young, M., & Chou, C. P. (2016b). Development of
a CRISPR‐Cas9 toolkit for comprehensive engineering of Bacillus.
Applied and Environmental Microbiology, 82(16), 4876–4895.
Wierson, W. A., Simone, B. W., Warejoncas, Z., Mann, C., Welker, J. M.,
Gendron, W. A. C., & Essner, J. J. (2019). Expanding the CRISPR
toolbox with ErCas12a in zebrafish and human cells. BioRxiv, https://
doi.org/10.1101/650515
Wilson, L. O. W., O'Brien, A. R., & Bauer, D. C. (2018). The current state
and future of CRISPR‐Cas9 gRNA design tools. Frontiers in
Pharmacology, 9, 749. https://doi.org/10.3389/fphar.2018.00749
Xu, J., Lian, W., Jia, Y., Li, L., & Huang, Z. (2017). Optimized guide RNA
structure for genome editing via Cas9. Oncotarget, 8(55),
94166–94171. https://doi.org/10.18632/oncotarget.21607
Yamano, T., Nishimasu, H., Zetsche, B., Ishitani, R., Zhang, F.,
Correspondence, O. N., & Nureki, O. (2016). Crystal structure of Cpf1
in complex with guide RNA and target DNA. Cell, 165, 949–962.
https://doi.org/10.1016/j.cell.2016.04.003
Yang, L., Zhang, X., Wang, L., Yin, S., Zhu, B., Xie, L., & Li, D. (2018).
Increasing targeting scope of adenosine base editors in mouse and
rat embryos through fusion of TadA deaminase with Cas9
variants. Protein & Cell, 9(9), 814–819. https://doi.org/10.1007/
s13238‐018‐0568‐x
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M.,
Makarova, K. S., Essletzbichler, P., & Zhang, F. (2015). Cpf1 is a single
RNA‐guided endonuclease of a class 2 CRISPR‐cas system. Cell,
163(3), 759–771. https://doi.org/10.1016/j.cell.2015.09.038
Zhang, K., Duan, X., & Wu, J. (2016). Multigene disruption in
undomesticated Bacillus subtilis ATCC 6051a using the CRISPR/Cas9
system. Scientific Reports, 6(27943), 1–11.
Zhang, X. Z., Yan, X., Cui, Z. L., Hong, Q., & Li, S. P. (2006). mazF, a novel
counter‐selectable marker for unmarked chromosomal manipulation
in Bacillus subtilis. Nucleic Acids Research, 34(9), e71. https://doi.org/10.
1093/nar/gkl358
Zhu, X., Zhao, D., Qiu, H., Fan, F., Man, S., Bi, C., & Zhang, X. (2017). The
CRISPR/Cas9‐facilitated multiplex pathway optimization (CFPO)
technique and its application to improve the Escherichia coli xylose
PRICE ET AL. | 11
utilization pathway. Metabolic Engineering, 43, 37–45. https://doi.org/
10.1016/j.ymben.2017.08.003
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section.
How to cite this article: Price MA, Cruz R, Bryson J, Escalettes
F, Rosser SJ. Expanding and understanding the CRISPR toolbox
for Bacillus subtilis with MAD7 and dMAD7. Biotechnology and
Bioengineering. 2020;1–12. https://doi.org/10.1002/bit.27312
12 | PRICE ET AL.
